Manufacturing Partnership with Made Scientific

Summary by AI BETAClose X

Hemogenyx Pharmaceuticals has announced a manufacturing partnership with Made Scientific to advance HG-CT-1, its CAR-T therapy for relapsed/refractory acute myeloid leukemia (r/r AML) in adults. Hemogenyx Pharmaceuticals will leverage Made Scientific's expertise in CAR-T cell therapy technology transfer and manufacturing at its GMP facilities in Newark and Princeton, NJ. These facilities are equipped for both clinical and commercial supply of cell therapies. This collaboration aims to accelerate the ongoing Phase I clinical trial of HG-CT-1 in adult patients and potentially include additional cohorts for pediatric r/r AML patients. Early clinical data supports growing confidence in both safety and potential efficacy of the therapy.

Disclaimer*

UK 100

Latest directors dealings